Navigation Links
Helix BioPharma Announces $13.5 Million Private Placement
Date:9/3/2009

AURORA, Ontario, Sept. 4 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: "HXBPF") today announced that it has accepted subscriptions for the purchase, by way of private placement, of a total of 6,625,000 units at $2.05 per unit, for gross proceeds totaling CDN$13,581,250. The Company anticipates closing the private placement by September 11, 2009.

Each unit consists of one common share and one common share purchase warrant, with each common share purchase warrant entitling the holder to purchase one common share of the Company at a price of $2.87 for up to three years after the closing date of the private placement. Proceeds of the placement will be used for working capital to support the Company's expanding clinical trial initiatives.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha- 2b. Helix is listed on the TSX and FSE under the symbol "HBP" and the OTCQX International Market under the symbol "HXBPF".

    For further information contact:

    Investor & Media Relations
    Robert Flamm, Ph.D.                       Ian Stone
    Russo Partners LLC                        Russo Partners LLC
    Tel: (212) 845-4226                       Tel: (619) 814-3510
    robert.flamm@russopartnersllc.com         Fax: (619) 955-5318
    www.russopartnersllc.com                  ian.stone@russopartnersllc.com

This News R
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
2. Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses
3. New and Updated Online Tutorials for dbGaP, GAD, and DGV from OpenHelix
4. Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
5. Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
6. Helix BioPharma to Present at the BioFinance 2009 Conference
7. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
8. Helix BioPharma Announces Q2 2009 Financial Results
9. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
10. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
11. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015  Traverse Biosciences announced today that ... development agreement (CRADA) with Aratana Therapeutics Inc. (NASDAQ: ... TRB-N0224 for the treatment and control of periodontal ... Traverse Biosciences has also granted Aratana an exclusive ... control of periodontal disease in companion animals, inclusive ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Achieved primarily ... produces slides that boast 10 to 100x better detail ... the capabilities of all existing light microscopy methods, it ... micrographs were chosen as the frame of reference because ... , The goal from the earliest discovery days ...
(Date:5/4/2015)... --  Intrexon Corporation (NYSE: XON ) today ... after the market closes on May 11, 2015.  The ... 5:30 PM ET to discuss the results and provide ... may be accessed by dialing 1-888-346-3959 (Domestic US) and ... Call."  Participants may also access the live webcast through ...
(Date:5/1/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), ... it has priced an underwritten registered offering of 3,900,000 ... $9.00 per share, and granted the underwriters in the ... additional 585,000 shares of its common stock. The gross ... is expected to close on May 6, 2015, subject ...
Breaking Biology Technology:Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 3Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 4Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3
... NY Researchers from the U.S. Department of Energy,s ... developed a new instrument that allows them to control ... 100 atoms with atomic precision. They created a ... developing the next generation of materials to be used ...
... Allscripts, the leading,provider of clinical software, ... improve healthcare, and the founding member of ... its firm support for the United States ... for physicians to adopt,electronic prescribing, or "e-prescribing," ...
... - Appeal of Compensatory Award Will Now Proceed -, ... today that its motion for judgment as a matter of ... of Donna Scroggin v.,Wyeth, in the U.S. District Court, Eastern ... vacates the punitive damages award of,$19,360,000 rendered by the Little ...
Cached Biology Technology:Controlling the size of nanoclusters: First step in making new catalysts 2National ePrescribing Patient Safety Initiative Supports Senate's Call for Physicians to Adopt Electronic Prescribing, Improving Patient Safety 2National ePrescribing Patient Safety Initiative Supports Senate's Call for Physicians to Adopt Electronic Prescribing, Improving Patient Safety 3National ePrescribing Patient Safety Initiative Supports Senate's Call for Physicians to Adopt Electronic Prescribing, Improving Patient Safety 4Wyeth's Motion to Overturn Punitive Damages Award Granted by Arkansas Court 2Wyeth's Motion to Overturn Punitive Damages Award Granted by Arkansas Court 3
(Date:4/1/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces the second shipment of a ... early access pre-order customers. Feedback from ... including Walmart, Target, AT&T, Dunkin, Donuts, Stop & Shop ... all outlets and very easy to use. Several users ...
(Date:3/31/2015)... YORK , March 31, 2015   Guidepoint ... the launch of the Post-Surgical Pain Management TRACKER, part ... products tracking usage trends in the medical device and ... access to data including treatment volumes, market share, and ... the pain associated with joint surgery. The ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... the "Global Iris Recognition Market 2015-2019" report ... Global Iris Recognition market to grow at a CAGR ... This report covers the present scenario and the growth ... period 2015-2019. To calculate the market size, the report ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... of Adelaide are a promising step forward in helping ... babies, by reducing the likelihood of adverse inflammatory responses to ... medical procedures experienced by preterm babies, who are often anemic ... Adelaide,s Robinson Institute studied 28 preterm babies (at ...
... is a serious complication of pregnancy and the major cause ... the U.S. It affects about one in 20 pregnancies. The ... urine. The cause of preeclampsia is still unclear. Dr. Florian ... Delbrck Center (MDC) and the Charit), Dr. Ralf Dechend (ECRC ...
... causes of dementia. In Germany and Switzerland alone, around ... doubling of the number of patients worldwide within the ... including amyloid- (Aβ) among others, in patients, brains plays ... from the Department of Neuropathology at Charit and his ...
Cached Biology News:Better blood transfusions for preterm babies 2New risk factor identified for high blood pressure during pregnancy 2New risk factor identified for high blood pressure during pregnancy 3New risk factor identified for high blood pressure during pregnancy 4Alzheimer's disease in mice alleviated promising therapeutic approach for humans 2
... solid. PROTECT FROM LIGHT. Useful in cell activation experiments ... ≥98% by TLC. Soluble in DMSO or EtOH. ... 10 mM stock in DMSO is recommended. Microliter amounts ... O with rapid mixing (e.g. 10 μl into 5 ...
... [RET-P1] to Rhodopsin Rhodopsin is a ... mammals, birds, amphibians, and reptiles. The rhodopsin ... in the retina. Immunogen: ... Specificity: This antibody specifically labels ...
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
Mouse polyclonal antibody to BTG2 - BTG family, member 2...
Biology Products: